

22 January 2020

**Our Ref:** RFI 32715

Dear

**Freedom of Information Act 2000  
Information Requested in Relation to Treatment of Lung and Melanoma  
Patients**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 20 December 2019.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Kelly**  
**Information Governance Assistant**

**Q1. How many melanoma patients currently undergoing treatment are BRAF+ ?**

A1. The information requested is not centrally held. To obtain this information would require a manual review of records to include reviewing all patients both diagnosed in the timeframes requested and all patients already undergoing treatment. This would need an audit approach as it involves interrogating numerous electronic systems across both South Eastern Trust and Belfast Trust sites (for pathology).

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

*12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.*

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.

**Q2. In the past 3 months, how many melanoma patients were treated with the following:**

**Bevacizumab**

**Cobimetinib**

**Dabrafenib**

**Dabrafenib AND trametinib**

**Dacarbazine**

**Encorafenib AND binimetinib**

**Ipilimumab**

**Ipilimumab AND Nivolumab**

**Nivolumab**

**Pembrolizumab**

**Trametinib**

**Vemurafenib**

**Vemurafenib AND Cobimetinib**

**Other active systemic anti-cancer therapy**

**Palliative care**

**In the past 3 months how many patients were seen who had stage III resectable melanoma**

**Of all stage III patients seen, how many received a complete resection?**

**Of all stage III patients seen, how many were stage III a?**

A2. Melanoma patients received their Systemic Anti-Cancer Therapy (SACT) in the Belfast Trust. You may wish to contact the Belfast Trust at; [publicliaison@belfasttrust.hscni.net](mailto:publicliaison@belfasttrust.hscni.net)

**Q3. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for Non-small cell lung cancer (NSCLC )**

A3. There were 58 patients diagnosed with lung cancer in SET within the last 3 months.

SACT drugs used are listed below:

Afatinib 0

Alectinib 1

Atezolizumab + bevacizumab + carboplatin + paclitaxel 0

Atezolizumab mono 5

Bevacizumab 0

Brigatinib 0

Ceritinib 2

Crizotinib 0

Dacomitinib 0

Docetaxel monotherapy 0

Durvalumab 1

Erlotinib 0

Gefitinib 3

Gemcitabine 0 as single agent

Necitumumab 0

Nintedanib with docetaxel 0

Nivolumab 0

Osimertinib 3

Paclitaxel 0

Pembrolizumab chemo in combination 0

Pembrolizumab monotherapy 4

Pemetrexed 0

Pemetrexed with carboplatin 8

Pemetrexed with cisplatin 0

Ramucirumab 0

Vinorelbine and cisplatin / carboplatin 0

Other active systemic anti-cancer therapy

Palliative care